About the webinar:
Alzheimer’s disease (AD) is characterized by progressive cognitive decline alongside early neuropsychiatric symptoms, including anxiety, agitation, and mood disturbances, which remain poorly addressed by current therapies. The ARTE10 transgenic mouse model, which co-expresses human APP and PS1 mutations, develops robust amyloid-β (Aβ) pathology and offers a platform to study both pathological and behavioural disease features.
In this webinar, we present a comprehensive characterization of the ARTE10 model across prodromal (5-month) and disease-stage (10-month) time points, focusing on behavioural phenotypes and translational biomarkers. ARTE10 mice display early and progressive anxiety-like behaviours, mood disturbances, and hyperactivity, with cognitive impairments emerging at later stages. These behavioural changes are accompanied by robust biomarker changes in fluid samples and across brain regions. Biomarker profiling revealed elevated Aβ42/40 ratios and increased neurofilament light (NfL) levels in brain, CSF, and plasma, reflecting both pathological progression and neurodegeneration. Notably, behavioural readouts show associations with amyloid load, supporting functional links between pathology and phenotype.
Together, these findings demonstrate that the ARTE10 model captures both core AD pathology and clinically relevant neuropsychiatric features, providing a translationally relevant system for evaluating therapeutic strategies targeting disease progression and comorbid symptom domains.
